FIRE Funds Wealth Builder ETF FIRS 深 滬
已收盤 10-24 16:00:00 美东时间
23.0775
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 23.0775
- 總市值 253.85万
- 52周最高 24.83
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 19.0245
- 委 比 0.00%
- 總股本 11.00万
- 歷史最高 24.83
- 量 比 0
- 振 幅 0.00%
- 歷史最低 19.0245
- 每 手 1
- 風險率 1.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FOCUS-On Canada's tariff frontline, business stalls over US trade deal jitters
FOCUS-On Canada's tariff frontline, business stalls over US trade deal jitters Windsor businesses face uncertainty ahead of USMCA review Trump's tariff threats disrupt Windsor's manufacturing sector Skilled training courses have suffered because of low demand Residential sales, prices fell faster th
03-28 18:00
BRIEF-Anaptys Announces $100 Million Stock Repurchase Plan And Provides A Business Update
BRIEF-Anaptys Announces $100 Million Stock Repurchase Plan And Provides A Business Update AnaptysBio Inc ANAB.O : ANAPTYS ANNOUNCES $100 MILLION STOCK REPURCHASE PLAN AND PROVIDES A BUSINESS UPDATE ANAPTYSBIO INC - TO SPIN-OFF BIOPHARMA OPERATIONS INTO FIRST TRACKS BIOTHERAPEUTICS ON APRIL 20, 2026
03-27 21:04
BRIEF-Anaptys Board Of Directors Approves Spin-Off Of First Tracks Biotherapeutics
BRIEF-Anaptys Board Of Directors Approves Spin-Off Of First Tracks Biotherapeutics AnaptysBio Inc ANAB.O : ANAPTYS BOARD OF DIRECTORS APPROVES SPIN-OFF OF FIRST TRACKS BIOTHERAPEUTICS Source text: ID:nGNX4WVKfC Further company coverage: ANAB.O
03-27 21:03
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval March 27 (Reuters) - Sanofi SA SASY.PA : SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION ADMINISTERED VIA ON-BODY INJECTOR RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT MULTIPLE MYELOMA IF APPROVED, SARCL
03-27 20:03
BRIEF-GSK Says Bepirovirsen Accepted For Review By EMA
BRIEF-GSK Says Bepirovirsen Accepted For Review By EMA March 27 (Reuters) - GSK plc GSK.L : BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA EMA ACCEPTS BEPIROVIRSEN FOR REVIEW AS POTENTIAL FIRST-IN-CLASS CHRONIC HEPATITIS B TREATMENT (( Reuters.Briefs@thomsonreuters.com ;;))
03-27 15:17
BRIEF-Sol Rashidi, World’S First Chief Ai Officer, Joins Agenda At Fico World 2026
BRIEF-Sol Rashidi, World’S First Chief Ai Officer, Joins Agenda At Fico World 2026 Fair Isaac Corp FICO.N : SOL RASHIDI, WORLD’S FIRST CHIEF AI OFFICER, JOINS AGENDA AT FICO WORLD 2026 Source text: ID:nBw5KBqJGa Further company coverage: FICO.N
03-26 20:56
BRIEF-Jushi Holdings Inc. Announces First Settlement In Ongoing Hemp-Derived Thc Litigation
BRIEF-Jushi Holdings Inc. Announces First Settlement In Ongoing Hemp-Derived Thc Litigation Jushi Holdings Inc JUSH.CD : JUSHI HOLDINGS INC. ANNOUNCES FIRST SETTLEMENT IN ONGOING HEMP-DERIVED THC LITIGATION Source text: ID:nGNX8DzphC Further company coverage: JUSH.CD
03-25 20:53
BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1
BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1 Sarepta Therapeutics Inc SRPT.O : SAREPTA ANNOUNCES FIRST CLINICAL DATA FROM SIRNA PIPELINE TARGETING FSHD1 AND DM1 SAREPTA THERAPEUTICS INC - SIRNA ACHIEVES HIGH MUSCLE CONCENTRATIONS WITHOUT DOSE LIMITING TOXIC
03-25 20:29
US judge to weigh Anthropic's bid to undo Pentagon blacklisting
US judge to weigh Anthropic's bid to undo Pentagon blacklisting Anthropic challenges Pentagon's national security risk designation Defense Department says Claude usage terms constrain military Anthropic opposes AI use in surveillance and autonomous weapons By Jack Queen March 24 (Reuters) - A U.S. j
03-24 22:49
BRIEF-Zillow Group Inc Reaffirms First-Quarter, Full-Year Outlook And Mid-Cycle Targets
BRIEF-Zillow Group Inc Reaffirms First-Quarter, Full-Year Outlook And Mid-Cycle Targets Zillow Group Inc ZG.O : ZILLOW GROUP INC: REAFFIRMS FIRST-QUARTER, FULL-YEAR OUTLOOK AND MID-CYCLE TARGETS ZILLOW GROUP INC - MID-CYCLE TARGETS: $5 BILLION REVENUE, 45% ADJUSTED EBITDA MARGIN, 25% NET INCOME MARG
03-24 20:53
